The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer

Immunological Investigations

Volumn 44, Issue 6, 2015, Pages 578-589

  Wang, Zhenxin ^a,b   Zhu, Jinlian ^a   Gu, Haidi ^a   Yuan, Yuan ^c   Zhang, Bin ^a   Zhu, Dongming ^a   Zhou, Jian ^a   Zhu, Yibei ^b   Chen, Weichang ^b  

^a Department of Medical Oncology ^*  (China)

^b SOOCHOW UNIVERSITY   (China)

^c HEBEI UNITED UNIVERSITY   (China)

Author keywords

gastric cancer; natural killer cells; T bet; Tim 3; tumor progression

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CELL PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3 PROTEIN; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HAVCR2 PROTEIN, MOUSE; MEMBRANE PROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21; VIRUS RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER GROWTH; CANCER INFILTRATION; CANCER PATIENT; CANCER STAGING; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; STOMACH CANCER; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL LINE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; STOMACH TUMOR;

ANIMALS; CELL LINE; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; RECEPTORS, VIRUS; STOMACH NEOPLASMS; T-BOX DOMAIN PROTEINS;

EID: 84939245512     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2015.1052145     Document Type: Article

References (22)

1. Anderson AC. (2012). Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol, 24, 213-16
2. Anderson AC, Anderson DE, Bregoli L, et al. (2007). Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science, 318, 1141-3
3. Anderson AC, Lord GM, Dardalhon V, et al. (2010). T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol, 40, 859-66
4. Dardalhon V, Anderson AC, Karman J, et al. (2010). Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 185, 1383-92
5. da Silva IP, Gallois A, Jimenez-Baranda S, et al. (2012). Tim-3 expression and function in natural killer cells from advanced melanoma patients. Cancer Res, 72, 5410
6. Fourcade J, Sun Z, Benallaoua M, et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med, 207, 2175-86
7. Frisancho-Kiss S, Nyland JF, Davis SE, et al. (2006). Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol, 176, 6411-15
8. Gao X, Zhu Y, Li G, et al. (2012). TIM-3 expression characterizes regulatory t cells in tumor tissues and is associated with lung cancer progression. PLoS One, 7, 30676
9. Gleason MK, Lenvik TR, McCullar V, et al. (2012). Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood, 119, 3064-72
10. Huang X, Bai X, Cao Y, et al. (2010). Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med, 207, 505-2
11. Ju Y, Hou N, Meng J, et al. (2010). T cell immunoglobulin-and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol, 52, 322-9
12. McIntire JJ, Umetsu SE, Akbari O, et al. (2001). Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol, 2, 1109-16
13. Monney L, Sabatos CA, Gaglia JL, et al. (2002). Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 415, 536-41
14. Nakae S, Iikura M, Suto H, et al. (2007). TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood, 110, 2565-8
15. Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. (2012). Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood, 119, 3734-43
16. Oikawa T, Kamimura Y, Akiba H, et al. (2006). Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol, 177, 4281-7
17. Sakuishi K, Apetoh L, Sullivan JM, et al. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207, 2187-94
18. Sánchez-Fueyo A, Tian J, Picarella D, et al. (2003). Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nat Immunol, 4, 1093-101
19. Yang ZZ, Grote DM, Ziesmer SC, et al. (2012). IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest, 122, 1271-82
20. Zhou Q, Munger ME, Veenstra RG, et al. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117, 4501-10
21. Zhu C, Aderson AC, Schubart A, et al. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type I immunity. Nat Immunol, 6, 1245
22. Zou W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5, 263-74